GlaxoSmithKline (GSK) and University College London's Institute of Ophthalmology have agreed a deal in which the Institute will investigate the potential of compounds provided by GSK's ophthalmic unit, Ophthiris.
Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.